The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

The Lancet

Volumn 387, Issue 10035, 2016, Pages 2302-2311

  Hijazi, Ziad ^a   Oldgren, Jonas ^a   Lindbäck, Johan ^a   Alexander, John H ^b   Connolly, Stuart J ^c   Eikelboom, John W ^c   Ezekowitz, Michael D ^d   Held, Claes ^a   Hylek, Elaine M ^e   Lopes, Renato D ^b   Siegbahn, Agneta ^a   Yusuf, Salim ^c   Granger, Christopher B ^b   Wallentin, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; APIXABAN; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; DABIGATRAN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN; HIGH SENSITIVITY CARDIAC TROPONIN T; NONSTEROID ANTIINFLAMMATORY AGENT; TROPONIN T; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREDICTIVE VALUE; PRIORITY JOURNAL; VALIDATION STUDY; CEREBROVASCULAR ACCIDENT; COMPLICATION; CONTROLLED STUDY; HEMORRHAGE; METABOLISM; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOMARKERS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; WARFARIN; YOUNG ADULT;

EID: 84975896253     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00741-8     Document Type: Article

References (34)

1. 1 Kannel, WB, Wolf, PA, Benjamin, EJ, Levy, D, Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82 (1998), 2N–9N.
2. 2 Hart, RG, Pearce, LA, Aguilar, MI, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
3. 3 Camm, AJ, Kirchhof, P, Lip, GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31 (2010), 2369–2429.
4. 4 January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130 (2014), e270–e271.
5. 5 Hijazi, Z, Lindback, J, Alexander, JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J, 2016 published online Feb 25. DOI: http://dx.doi.org/10.1093/eurheartj/ehw054.
6. 6 Pisters, R, Lane, DA, Nieuwlaat, R, de Vos, CB, Crijns, HJ, Lip, GY, A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 138 (2010), 1093–1100.
7. 7 O'Brien, EC, Simon, DN, Thomas, LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 36 (2015), 3258–3264.
8. 8 Hijazi, Z, Hohnloser, SH, Oldgren, J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 129 (2014), 961–970.
9. 9 Hijazi, Z, Siegbahn, A, Andersson, U, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 129 (2014), 625–634.
10. 10 Hijazi, Z, Wallentin, L, Siegbahn, A, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol 63 (2014), 52–61.
11. 11 Hohnloser, SH, Hijazi, Z, Thomas, L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33 (2012), 2821–2830.
12. 12 Hylek, EM, Held, C, Alexander, JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 63 (2014), 2141–2147.
13. 13 Wallentin, L, Hijazi, Z, Andersson, U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 130 (2014), 1847–1858.
14. 14 Hijazi, Z, Oldgren, J, Siegbahn, A, Granger, CB, Wallentin, L, Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 34 (2013), 1475–1480.
15. 15 Aulin, J, Siegbahn, A, Hijazi, Z, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J 170 (2015), 1151–1160.
16. 16 Christersson, C, Wallentin, L, Andersson, U, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. J Thromb Haemost 12 (2014), 1401–1412.
17. 17 Hijazi, Z, Aulin, J, Andersson, U, et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart 102 (2016), 508–517.
18. 18 Hijazi, Z, Wallentin, L, Siegbahn, A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 61 (2013), 2274–2284.
19. 19 Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
20. 20 Ezekowitz, MD, Connolly, S, Parekh, A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157 (2009), 805–810.
21. 21 Granger, CB, Alexander, JH, McMurray, JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
22. 22 Lopes, RD, Alexander, JH, Al-Khatib, SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159 (2010), 331–339.
23. 23 Moons, KG, Altman, DG, Reitsma, JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 162 (2015), W1–W73.
24. 24 Harrell, FE, Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis, 2015, Springer, New York, NY.
25. 25 Vickers, AJ, Cronin, AM, Elkin, EB, Gonen, M, Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak, 8, 2008, 53.
26. 26 Steyerberg, EW, Vergouwe, Y, Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J 35 (2014), 1925–1931.
27. 27 Royston, P, Altman, DG, External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol, 13, 2013, 33.
28. 28 Hagstrom, E, James, SK, Bertilsson, M, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J, 2015 published online Sept 28. http://dx.doi.org/10.1093/eurheartj/ehv491.
29. 29 Wallentin, L, Zethelius, B, Berglund, L, et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One, 8, 2013, e78797.
30. 30 Friberg, L, Rosenqvist, M, Lip, GY, Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33 (2012), 1500–1510.
31. 31 Kirchhof, P, Breithardt, G, Aliot, E, et al. Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 15 (2013), 1540–1556.
32. 32 Held, C, Hylek, EM, Alexander, JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J 36 (2015), 1264–1272.
33. 33 Hijazi, Z, Oldgren, J, Andersson, U, et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart 100 (2014), 1193–1200.
34. 34 Eckman, MH, Singer, DE, Rosand, J, Greenberg, SM, Moving the tipping point. Circ Cardiovasc Qual Outcomes 14 (2011), 14–21.